OBJECTIVE:To establish the bioassay of Rare category of Chinese medicine METHOD: To investigate the effects of aqueous extracts of Honeysuckle, Forsythia suspense (Thunb.)Vahl., Sophora flavescens Ait., Isatis tinctoria L. or Baphicacanthus cusia Bremek., Andrographis panicullata (Burm.f.)Nees., Houttuynia cordata Thunb. and Paeonia suffruticosa Andr. on inhibitiing the in vitro growth of CMCC bacteria (Escherichia Coli, Staphy lococus aureus, Bacillus subtilis ,Micrococcus luteus), and select the optimal CMCC bacteria for bioassay ; to determine the dose range of Forsythia suspense (Thunb.)Vahl. Andrographis panicullata (Burm.f.)Nees for bioassay, plot standard and dose-effect curves of Forsythia suspense (Thunb.)Vahl. and Andrographis panicullata (Burm.f.)Nees; to compare quality control parameters between bioassay and HPLC.To establish the one-point method of dose-effect model according to the bioassay method of antibiotic effect extent as described in Pharmacopoeia of the People's Republic of China (2000 edition) and plasma pharmacology, and assay the quality of Forsythia suspense (Thunb.)Vahl.and Andrographis panicullata (Burm.f.)Nees originated from different areas or medicinal products accodint to the HPLC method as described in Pharmacopoeia of the People's Republic of ChinaRESULTS: Forsythia suspense and Andrographis panicullata had a better effect on the four bacteria; Sophora flavescens Ait had a certain effect on four bacteria; Honeysuckle and Houttuynia cordata Thunb. had some effect on bacteria; Isatis tinctoria L. or Baphicacanthus cusia Bremek. and Paeonia suffruticosa Andr. had no effect on the four bacteria.There was a linear relationship between dose and effect in the special concentration range of Forsythia suspense (Thunb.)Vahl. and Andrographis panicullata (Burm.f.)Nees; based on that, bioassay can be used to indicate the dose of those plants. In addition, there were some differences of quality-control parameters between bioassay and HPLC. However, we couldnot determine which method was more reasonable in the trial of Plasma... |